Mutant OPAA enzymes with increased catalytic efficiency on cyclosarin
US10538749B1 · kind B1 · utility
0Cited by
7References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 19, 2018 |
| Grant date | Jan 21, 2020 |
| Priority date | — |
| Expiry date | Jun 2, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention comprises isolated, mutant, non-wild-type organophosphorus acid anhydrolase (OPAA) enzymes having two site mutations, methods of production, and methods of use to effectively degrade cylcosarin (GF) (cyclohexyl methylphosphonofluoridate) with greater catalytic efficiency than the wild-type OPAA.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.